IOVA vs NVS
Iovance Biotherapeutics, Inc. vs Novartis AG — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
| Metric | IOVA | NVS |
|---|
| AI Score |
67
|
75
|
| Price |
$6.49
|
$154.64
|
| P/E Ratio |
-9.27×
|
23.55×
|
| ROE |
-56.0%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
74.3%
|
| Debt / Equity |
0.06×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
79.2
|
57.7
|
| Beta |
0.701
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for IOVA versus NVS.
NVS leads by 8 points.
NVS scores 75/100 (Buy) versus IOVA at 67/100 (Buy).
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical